Breaking News

Biocon Completes Acquisition of Viatris’ Global Biosimilars Business

Creates an integrated, leading global biosimilars enterprise with eight commercialized products.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. has completed its multi-billion-dollar acquisition of the global biosimilars business of its partner Viatris Inc.   Biocon Biologics will recognize the combined revenue and associated profits from the acquired biosimilars products. The acquisition provides Biocon with direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets.   With this acquisition Biocon Biologics becomes ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters